PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

被引：335
作者：
Guerrero-Zotano, Angel [1 ,2 ]
Mayer, Ingrid A. [1 ,2 ]
Arteaga, Carlos L. [1 ,2 ]
机构：
[1] Vanderbilt Univ, Sch Med, Ctr Canc, Dept Med,Breast Canc Program,Vanderbilt Ingram, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Ctr Canc, Dept Canc Biol,Breast Canc Program,Vanderbilt Ing, Nashville, TN 37232 USA
来源：
CANCER AND METASTASIS REVIEWS | 2016年 / 35卷 / 04期
关键词：
PI3K; AKT; mTOR; Breast cancer; PHASE-I TRIAL; POSTMENOPAUSAL WOMEN; PIK3CA MUTATIONS; PHOSPHATIDYLINOSITOL; 3-KINASES; TRASTUZUMAB RESISTANCE; ADJUVANT TRASTUZUMAB; ESTROGEN DEPRIVATION; ANTITUMOR-ACTIVITY; ENDOCRINE THERAPY; MAMMALIAN TARGET;
D O I：
10.1007/s10555-016-9637-x
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.
引用
收藏
页码：515 / 524
页数：10
相关论文
共 81 条
[1]   Cooperation between Pik3ca and p53 Mutations in Mouse Mammary Tumor Formation [J].
Adams, Jessica R. ;
Xu, Keli ;
Liu, Jeff C. ;
Agamez, Natalia M. Ruiz ;
Loch, Amanda J. ;
Wong, Ruth G. ;
Wang, Wei ;
Wright, Katherine L. ;
Lane, Timothy F. ;
Zacksenhaus, Eldad ;
Egan, Sean E. .
CANCER RESEARCH, 2011, 71 (07) :2706-2717
[2]  
Agoulnik IU, 2011, ONCOTARGET, V2, P321
[3]   Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3 [J].
Andre, Fabrice ;
Hurvitz, Sara ;
Fasolo, Angelica ;
Tseng, Ling-Ming ;
Jerusalem, Guy ;
Wilks, Sharon ;
O'Regan, Ruth ;
Isaacs, Claudine ;
Toi, Masakazu ;
Burris, Howard ;
He, Wei ;
Robinson, Douglas ;
Riester, Markus ;
Taran, Tetiana ;
Chen, David ;
Slamon, Dennis .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (18) :2115-+
[4]   Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial [J].
Andre, Fabrice ;
O'Regan, Ruth ;
Ozguroglu, Mustafa ;
Toi, Masakazu ;
Xu, Binghe ;
Jerusalem, Guy ;
Masuda, Norikazu ;
Wilks, Sharon ;
Arena, Francis ;
Isaacs, Claudine ;
Yap, Yoon-Sim ;
Papai, Zsuzsanna ;
Lang, Istvan ;
Armstrong, Anne ;
Lerzo, Guillermo ;
White, Michelle ;
Shen, Kunwei ;
Litton, Jennifer ;
Chen, David ;
Zhang, Yufen ;
Ali, Shyanne ;
Taran, Tetiana ;
Gianni, Luca .
LANCET ONCOLOGY, 2014, 15 (06) :580-591
[5]  
[Anonymous], 2016, J CLIN ONCOLOGY S, V34
[6]  
[Anonymous], CLIN CANC RES
[7]  
[Anonymous], AM ASS CANC RES S2, DOI DOI 10.1158/1535-7163.TARG-15-B109
[8]   Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].
Bachelot, Thomas ;
Bourgier, Celine ;
Cropet, Claire ;
Ray-Coquard, Isabelle ;
Ferrero, Jean-Marc ;
Freyer, Gilles ;
Abadie-Lacourtoisie, Sophie ;
Eymard, Jean-Christophe ;
Debled, Marc ;
Spaeth, Dominique ;
Legouffe, Eric ;
Allouache, Djelila ;
El Kouri, Claude ;
Pujade-Lauraine, Eric .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724
[9]  
Baird R, 2016, J CLIN ONCOLOGY S, V34
[10]  
Baselga J, 2015, SABCS
123456789